Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents Publisher Pubmed



Khamisipour G1 ; Jadidiniaragh F2, 3, 4 ; Jahromi AS5 ; Zandi K6 ; Hojjatfarsangi M7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Hematology, Faculty of Allied Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
  2. 2. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Research Center for Non-Communicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
  6. 6. Tropical Infectious Diseases Research and Education Center, Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  7. 7. Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, SE-171 76, Sweden
  8. 8. Department of Immunology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

Source: Tumor Biology Published:2016


Abstract

Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug resistance proteins and ATP-binding cassette families, are cell membrane transporters that can efflux several substrates such as chemotherapy agents from the cell cytoplasm. To reduce the adverse effects of chemotherapy agents, various targeted-based cancer therapy (TBCT) agents have been developed. TBCT has revolutionized cancer treatment, and several agents have shown more specific effects on tumor cells than chemotherapies. Small molecule inhibitors and monoclonal antibodies are specific agents that mostly target tumor cells but have low side effects on normal cells. Although these agents have been very useful for cancer treatment, however, the presence of natural and acquired resistance has blunted the advantages of targeted therapies. Therefore, development of new options might be necessary. A better understanding of tumor cell resistance mechanisms to current treatment agents may provide an appropriate platform for developing and improving new treatment modalities. Therefore, in this review, different mechanisms of tumor cell resistance to chemotherapy drugs and current targeted therapies have been described. © 2016, International Society of Oncology and BioMarkers (ISOBM).
Related Docs
View other Related Docs
1. Ibrutinib-A Double-Edge Sword in Cancer and Autoimmune Disorders, Journal of Drug Targeting (2016)
2. Expression of Cd133 Cancer Stem Cell Marker in Melanoma: A Systematic Review and Meta-Analysis, International Journal of Biological Markers (2016)
3. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
4. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
5. Epigenetic of Retinoic Acid Receptor ß2 Gene in Breast Cancer, Epigenetics Territory and Cancer (2015)
6. Immunopathology and Immunotherapy of Myeloid Leukemia, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
7. Receptor Tyrosine Kinase-Like Orphan Receptor 1: A Novel Target for Cancer Immunotherapy, Expert Opinion on Therapeutic Targets (2015)
8. Cancer Stem Cell Research in Iran: Potentials and Challenges, Future Oncology (2017)
Experts (# of related papers)
View all Related Experts
Hamid Reza Mirzaei (4)
Nima Rezaei (4)
Other Related Docs
9. Dendritic Cell Based Immunotherapy Using Tumor Stem Cells Mediates Potent Antitumor Immune Responses, Cancer Letters (2016)
10. Deciphering Biological Characteristics of Tumorigenic Subpopulations in Human Colorectal Cancer Reveals Cellular Plasticity, Journal of Research in Medical Sciences (2016)
11. Local Immunotherapy of Glioblastoma: A Comprehensive Review of the Concept, Journal of Neuroimmunology (2023)
12. Glance Into Cancer Stem Cells, Journal of Kerman University of Medical Sciences (2016)
13. Recent Advances in Targeting Mtor Signaling Pathway Using Small Molecule Inhibitors, Journal of Drug Targeting (2017)
14. Spontaneous Immunity Against the Receptor Tyrosine Kinase Ror1 in Patients With Chronic Lymphocytic Leukemia, PLoS ONE (2015)
15. Monoclonal Antibody Against Ror1 Induces Apoptosis in Human Bladder Carcinoma Cells, Avicenna Journal of Medical Biotechnology (2020)
16. Investigation of Specific Binding of Designed Oligodeoxynucleotide Decoys to Transcription Factors in Ht29 Cell Line Undergoing Epithelial–Mesenchymal Transition (Emt), Journal of Cellular Physiology (2019)
17. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)
18. Cancer Stem-Like Cell Behavior in Anaplastic Thyroid Cancer: A Challenging Dilemma, Life Sciences (2016)
19. Comparative Gene-Expression Profiling of Cd133+ and Cd133- D10 Melanoma Cells, Future Oncology (2015)
20. Inhibition of Tumor Growth by Mouse Ror1 Specific Antibody in a Syngeneic Mouse Tumor Model, Immunology Letters (2018)
21. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)
22. Micrornas in Cancer, Synthesis Lectures on Biomedical Engineering (2022)
23. Functionalised Nanomaterials for Eradication of Cscs, a Promising Approach for Overcoming Tumour Heterogeneity, Journal of Drug Targeting (2018)
24. Cancer Stem Cell’S Potential Clinical Implications, International Journal of Cancer Management (2017)
25. The Role of Hypoxia-Inducible Factors in Breast Cancer Stem Cell Specification, Pathology Research and Practice (2023)
26. Targeting Bruton’S Tyrosine Kinase (Btk) As a Signaling Pathway in Immune-Mediated Diseases: From Molecular Mechanisms to Leading Treatments, Advances in Rheumatology (2024)
27. Current Approaches in Identification and Isolation of Cancer Stem Cells, Journal of Cellular Physiology (2019)
28. Exosomal Micrornas and Long Noncoding Rnas: Novel Mediators of Drug Resistance in Lung Cancer, Journal of Cellular Physiology (2022)
29. Differential Expression of Cancer Stem Cell Markers Aldh1 and Cd133 in Various Lung Cancer Subtypes, Cancer Investigation (2015)
30. Harnessing the Power of Exosomes for Diagnosis, Prognosis, and Treatment of Hematological Malignancies, Stem Cell Research and Therapy (2025)
31. A Review on Leukemia and Ipsc Technology: Application in Novel Treatment and Future, Current Stem Cell Research and Therapy (2018)
32. Personalized Medicine in Breast Cancer: Pharmacogenomics Approaches, Pharmacogenomics and Personalized Medicine (2019)
33. Does the Use of Melatonin Overcome Drug Resistance in Cancer Chemotherapy?, Life Sciences (2018)
34. Morphological and Molecular Characteristics of Spheroid Formation in Ht-29 and Caco-2 Colorectal Cancer Cell Lines, Cancer Cell International (2021)
35. Lung Cancer-Associated Brain Metastasis: Molecular Mechanisms and Therapeutic Options, Cellular Oncology (2017)
36. Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics, Frontiers in Oncology (2019)
37. Co-Expression of Cancer Stem Cell Markers Oct4 and Nanog Predicts Poor Prognosis in Renal Cell Carcinomas, Scientific Reports (2018)
38. Lncrnas Roles in Chemoresistance of Cancer Cells, Current Molecular Medicine (2022)
39. Breast Cancer: Biology, Biomarkers, and Treatments, International Immunopharmacology (2020)
40. Upregulation of Circulating Cancer Stem Cell Marker, Dclk1 But Not Lgr5, in Chemoradiotherapy-Treated Colorectal Cancer Patients, Tumor Biology (2015)
41. 6-Cinnamoyl-4-Arylaminothienopyrimidines As Highly Potent Cytotoxic Agents: Design, Synthesis and Structure-Activity Relationship Studies, European Journal of Medicinal Chemistry (2020)
42. Inhibition of Exosome Release Sensitizes U937 Cells to Pegylated Liposomal Doxorubicin, Frontiers in Immunology (2021)
43. Cancer Stem Cells and Oral Cancer: Insights Into Molecular Mechanisms and Therapeutic Approaches, Cancer Cell International (2020)
44. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)
45. Mesenchymal Stem/Stromal Cell-Derived Exosomes in Regenerative Medicine and Cancer; Overview of Development, Challenges, and Opportunities, Stem Cell Research and Therapy (2021)
46. Cancer Nanomedicine: Special Focus on Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
47. Nano-Delivery System Targeting to Cancer Stem Cell Cluster of Differentiation Biomarkers, Journal of Controlled Release (2017)
48. Diagnostic and Therapeutic Potential of Exosomes in Cancer: The Beginning of a New Tale?, Journal of Cellular Physiology (2017)
49. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
50. Targeting Cancer Stem Cell-Specific Markers And/Or Associated Signaling Pathways for Overcoming Cancer Drug Resistance, Tumor Biology (2016)